Nussenblatt R B, de Smet M D, Rubin B, Freidlin V, Whitcup S M, Davis J, Herman D, Bloom J N, Sran P K, Whitcher S
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Am J Ophthalmol. 1993 May 15;115(5):583-91. doi: 10.1016/s0002-9394(14)71454-0.
Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.
在一项剂量递增研究中，32例患有威胁视力的葡萄膜炎且视力下降需要全身治疗的患者被随机分配接受环孢素A或环孢素G治疗。两组患者均接受2.5毫克/千克体重/天至10毫克/千克体重/天的上述两种药物之一，并联合低剂量泼尼松治疗。更多服用环孢素G的患者视力得到改善，黄斑水肿减轻，且即使在较低测试剂量下，这种情况出现得也比另一组更快。在任何测试剂量下，两组之间的肾功能均无差异。4例接受环孢素G治疗的患者出现肝脏改变，但只有1例需要停药。该研究表明环孢素G具有潜在的应用价值，尤其是在较低剂量（4毫克/千克体重/天）时，这可能会降低严重肾脏并发症的发生风险。
